Patent · US Expired

Targeted combination immunotherapy of cancer

US6077499A · kind A · utility

173Cited by
11References
37Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 3, 1998
Grant dateJun 20, 2000
Priority date
Expiry dateNov 3, 2018

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2121/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides compositions, methods and kits for effecting therapy of a tumor in a patient. The compositions comprise (A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety selectively binds to a marker substance produced by or associated with the tumor; (B) optionally, a clearing composition; and (C) a second conjugate comprising a complementary member of the binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent. The methods comprise sequentially administering (A), (B), and (C) to a patient. The kits comprise (A), (B), and (C) in separate containers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.